Hrs-6093
Advanced KRAS G12D Mutant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Advanced KRAS G12D Mutant Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hrs-4642 Jiangsu HengRui Medicine Co., Ltd. | Phase 1/2 | CCC |
ETOPOSIDE Jiangsu HengRui Medicine Co., Ltd. | Phase 1/2 | CC |
Cetuximab Jiangsu HengRui Medicine Co., Ltd. | Phase 1/2 | CC |
CIS-DIAMMINEDICHLOROPLATINUM II Jiangsu HengRui Medicine Co., Ltd. | Phase 1/2 | CC |
Adebrelimab Jiangsu HengRui Medicine Co., Ltd. | Phase 1/2 | CC |
Shr-9839 Jiangsu HengRui Medicine Co., Ltd. | Phase 1/2 | CC |
Carboplatin Jiangsu HengRui Medicine Co., Ltd. | Phase 1/2 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →